TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have earned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $50.00.

Several analysts have commented on TGTX shares. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Thursday, January 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. Wall Street Zen lowered TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, JPMorgan Chase & Co. reduced their price target on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Danske Bank A S bought a new position in shares of TG Therapeutics in the third quarter valued at approximately $25,000. Optiver Holding B.V. boosted its holdings in shares of TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 732 shares during the period. Bessemer Group Inc. boosted its holdings in shares of TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 486 shares during the period. Salomon & Ludwin LLC acquired a new position in TG Therapeutics in the 3rd quarter valued at $34,000. Finally, Stone House Investment Management LLC acquired a new position in TG Therapeutics in the 3rd quarter valued at $36,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

TGTX opened at $33.53 on Friday. The company has a market capitalization of $5.35 billion, a PE ratio of 12.10 and a beta of 1.76. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.10 and a quick ratio of 3.29. TG Therapeutics has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The business has a 50-day moving average of $29.95 and a 200-day moving average of $31.52.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). The firm had revenue of $192.57 million during the quarter, compared to analyst estimates of $192.15 million. TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The company’s quarterly revenue was up 78.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.15 EPS. Equities research analysts forecast that TG Therapeutics will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.